Toll-like receptors and skin cancer

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Burns, Erin M ^a   Yusuf, Nabiha ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

BCC; Innate immunity; Melanoma; Non melanoma skin cancer; SCC; Toll like receptor

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; LIGAND; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VACCINE;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; MALIGNANT LENTIGO; MELANOCYTE; MOLECULARLY TARGETED THERAPY; NON MELANOMA SKIN CANCER; NONHUMAN; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

EID: 84897949357     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00135     Document Type: Article

References (69)

1. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 146(3):283-7. doi:10.1001/archdermatol.2010.19
2. American Cancer Society. What are the Risk Factors for Basal and Squamous Cell Skin Cancers. (2013). Available from: www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-risk-factors
3. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol (2013) 68(6):957-66.
4. The Lewin Group. The Burden of Skin Diseases 2005 Prepared for SID and The American Academy of Dermatology Association. (2005). Available from: www.lewin.com/~/media/lewin/site_sections/publications/april2005skindisease
5. American Cancer Society. Cancer Facts & Figures. (2013). Available from: www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
6. Bensouliah J, Buck P. Skin structure and function. In: Bensouliah J, Buck P, editors. Aromadermatology: Aromatherapy in the Treatment and Care of Common Skin Conditions. Abingdon: Radcliffe Publishing Ltd (2006). p. 1-11.
7. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol (2004) 4(3):211-22. doi:10.1038/nri1310
8. Dinulos JG, Mentele L, Fredericks LP, Dale BA, Darmstadt GL. Keratinocyte expression of human beta defensin 2 following bacterial infection: role in cutaneous host defense. Clin Diagn Lab Immunol (2003) 10(1):161-6. doi:10.1128/CDLI.10.1.161-166.2003
9. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species. Infect Immun (2004) 72(1):352-8. doi:10.1128/IAI.72.1.352-358.2004
10. Song PI, Park YM, Abraham T, Harten B, Zivony A, Neparidze N, et al. Human keratinocytes express functional CD14 and toll-like receptor 4. J Invest Dermatol (2002) 119(2):424-32. doi:10.1046/j.1523-1747.2002.01847.x
11. Kawai K, Shimura H, Minagawa M, Ito A, Tomiyama K, Ito M. Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J Dermatol Sci (2002) 30(3):185-94. doi:10.1016/S0923-1811(02)00105-6
12. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol (2003) 148(4):670-9. doi:10.1046/j.1365-2133.2003.05287.x
13. Pivarcsi A, Bodai L, Rethi B, Kenderessy-Szabo A, Koreck A, Szell M, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol (2003) 15(6):721-30. doi:10.1093/intimm/dxg068
14. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol (2007) 127(2):331-41. doi:10.1038/sj.jid.5700530
15. Jin SH, Kang HY. Activation of Toll-like Receptors 1, 2, 4, 5, and 7 on Human melanocytes modulate pigmentation. Ann Dermatol (2010) 22(4):486-9. doi:10.5021/ad.2010.22.4.486
16. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 85(2):85-95. doi:10.1016/S0165-2478(02)00228-6
17. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol (2004) 25(7):381-6. doi:10.1016/j.it.2004.04.011
18. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:335-76. doi:10.1146/annurev.immunol.21.120601.141126
19. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 1(2):135-45. doi:10.1038/35100529
20. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med (2000) 343(5):338-44. doi:10.1056/NEJM200008033430506
21. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5(10):987-95. doi:10.1038/ni1112
22. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 2(8):675-80. doi:10.1038/90609
23. Kang HY, Park TJ, Jin SH. Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol (2009) 129(1):243-6. doi:10.1038/jid.2008.184
24. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2007) 81(1):1-5. doi:10.1189/jlb.0306164
25. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 14(11):2592-603. doi:10.1111/j.1582-4934.2010.01127.x
26. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 220:60-81. doi:10.1111/j.1600-065X.2007.00579.x
27. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418(6894):191-5. doi:10.1038/nature00858
28. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 11(1):91-9. doi:10.1007/s10456-008-9093-5
29. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499-511. doi:10.1038/nri1391
30. Kawai T, Akira S. TLR signaling. Semin Immunol (2007) 19(1):24-32. doi:10.1016/j.smim.2006.12.004
31. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 2(4):301-10. doi:10.1038/nrc780
32. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
33. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res (2005) 93:159-87. doi:10.1016/S0065-230X(05)93005-4
34. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron (2009) 2(Suppl 1):205-14. doi:10.1007/s12307-009-0022-y
35. Wu J, Guan M, Wong PF, Yu H, Dong J, Xu J. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. Food Chem Toxicol (2012) 50(9):3019-24. doi:10.1016/j.fct.2012.06.027
36. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, et al. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 7(11):3642-53. doi:10.1158/1535-7163.MCT-08-0582
37. Saint-Jean M, Knol AC, Nguyen JM, Khammari A, Dreno B. TLR expression in human melanoma cells. Eur J Dermatol (2011) 21(6):899-905. doi:10.1684/ejd.2011.1526
38. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 13(15 Pt 1):4565-74. doi:10.1158/1078-0432.CCR-07-0274
39. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J (2010) 29(13):2242-52. doi:10.1038/emboj.2010.94
40. Di JM, Pang J, Sun QP, Zhang Y, Fang YQ, Liu XP, et al. Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol Biol Rep (2010) 37(4):1849-55. doi:10.1007/s11033-009-9620-5
41. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther (2007) 6(11):1704-9. doi:10.4161/cbt.6.11.4826
42. Di JM, Pang J, Pu XY, Zhang Y, Liu XP, Fang YQ, et al. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet (2009) 192(2):60-7. doi:10.1016/j.cancergencyto.2009.03.006
43. Chuang HC, Huang CC, Chien CY, Chuang JH. Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncol (2012) 48(3):226-32. doi:10.1016/j.oraloncology.2011.10.008
44. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 65(12):5009-14. doi:10.1158/0008-5472.CAN-05-0784
45. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 6(1):e10. doi:10.1371/journal.pmed.1000010
46. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother (2005) 28(3):220-8. doi:10.1097/01.cji.0000156828.75196.0d
47. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol (2003) 171(10):4984-9.
48. Bianchi L, Campione E, Marulli GC, Costanzo A, Chimenti S. Actinic keratosis treated with an immune response modifier: a case report of six patients. Clin Exp Dermatol (2003) 28(Suppl 1):39-41. doi:10.1046/j.1365-2230.28.s1.13.x
49. Bianchi L, Costanzo A, Campione E, Nistico S, Chimenti S. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients. Clin Exp Dermatol (2003) 28(Suppl 1):24-6. doi:10.1046/j.1365-2230.28.s1.13.x
50. Chen K, Shumack S. Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream. Clin Exp Dermatol (2003) 28(Suppl 1):10-2. doi:10.1046/j.1365-2230.28.s1.4.x
51. Giannotti B, Vanzi L, Difonzo EM, Pimpinelli N. The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin. Clin Exp Dermatol (2003) 28(Suppl 1):33-5. doi:10.1046/j.1365-2230.28.s1.11.x
52. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol (2003) 149(Suppl 66):66-70. doi:10.1046/j.0366-077X.2003.05637.x
53. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 149(Suppl 66):53-6. doi:10.1046/j.0366-077X.2003.05626.x
54. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3(2):196-200. doi:10.1038/ni758
55. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg (2004) 8(5):338-52. doi:10.1007/s10227-005-0023-5
56. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis (2004) 9(3):291-8. doi:10.1023/B:APPT.0000025805.55340.c3
57. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol (2002) 47(3):390-8. doi:10.1067/mjd.2002.126215
58. Kaporis HG, Guttman-Yassky E, Lowes MA, Haider AS, Fuentes-Duculan J, Darabi K, et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol (2007) 127(10):2391-8. doi:10.1038/sj.jid.5700884
59. Yokogawa M, Takaishi M, Nakajima K, Kamijima R, Digiovanni J, Sano S. Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells. Mol Carcinog (2013) 52(10):760-9. doi:10.1002/mc.21901
60. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol (2003) 149(Suppl 66):57-8. doi:10.1046/j.0366-077X.2003.05630.x
61. Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs (2013) 22(1):149-59. doi:10.1517/13543784.2013.749236
62. Wang J, Kobayashi M, Han M, Choi S, Takano M, Hashino S, et al. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol (2002) 118(2):638-45. doi:10.1046/j.1365-2141.2002.03645.x
63. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep (2004) 6(2):88-95. doi:10.1007/s11912-004-0019-0
64. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother (2008) 31(5):520-7. doi:10.1097/CJI.0b013e318174a4df
65. Garcia-Zuazaga J, Olbricht SM. Cutaneous squamous cell carcinoma. Adv Dermatol (2008) 24:33-57. doi:10.1016/j.yadr.2008.09.007
66. Eiro N, Ovies C, Fernandez-Garcia B, Alvarez-Cuesta CC, Gonzalez L, Gonzalez LO, et al. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res (2013) 305(1):59-67. doi:10.1007/s00403-012-1300-y
67. Broad A, Kirby JA, Jones DE, Applied I, Transplantation Research G. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology (2007) 120(1):103-11. doi:10.1111/j.1365-2567.2006.02485.x
68. de Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van't Veer C, van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol (2009) 183(1):533-42. doi:10.4049/jimmunol.0802189
69. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res (2011) 71(15):5123-33. doi:10.1158/0008-5472.CAN-10-3903